NASDAQ:NDRM - Neuroderm Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$38.85 0.00 (0.00 %)
(As of 05/27/2018 03:59 PM ET)
Previous Close$38.85
Today's Range$38.85 - $38.85
52-Week Range$15.20 - $38.95
VolumeN/A
Average Volume418,712 shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Neuroderm (NASDAQ:NDRM)

Neuroderm logoNeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson's disease, as well as other CNS diseases. The Company's Parkinson's disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701. It is developing ND0612H for the treatment of patients suffering from severe Parkinson's disease. It is developing ND0612L for the treatment of patients at the moderate stage of Parkinson's disease that can no longer control motor complications with oral levodopa. It has also designed ND0701, which is an apomorphine-based product. ND0701 is for patients suffering from Parkinson's disease, may be used mostly by patients suffering from high motor fluctuations and not responding well to LD/CD.

Receive NDRM News and Ratings via Email

Sign-up to receive the latest news and ratings for NDRM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:NDRM
CUSIPN/A
Phone+972-8-9462729

Debt

Debt-to-Equity RatioN/A
Current Ratio17.69
Quick Ratio17.69

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-44.69%
Return on Assets-42.41%

Miscellaneous

Employees55
Outstanding Shares26,350,000

Neuroderm (NASDAQ:NDRM) Frequently Asked Questions

What is Neuroderm's stock symbol?

Neuroderm trades on the NASDAQ under the ticker symbol "NDRM."

How were Neuroderm's earnings last quarter?

Neuroderm Ltd (NASDAQ:NDRM) announced its quarterly earnings results on Thursday, May, 11th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.38) by $0.13. View Neuroderm's Earnings History.

What price target have analysts set for NDRM?

6 brokers have issued 12-month target prices for Neuroderm's stock. Their forecasts range from $39.00 to $47.00. On average, they expect Neuroderm's share price to reach $41.8333 in the next year. View Analyst Ratings for Neuroderm.

Who are Neuroderm's key executives?

Neuroderm's management team includes the folowing people:
  • Robert Taub, Chairman of the Board
  • Oded S. Liebermann, Chief Executive Officer, Director
  • Roy Golan CPA, Chief Financial Officer
  • , Bio & Compensation - 
  • Tami Yardeni, Chief Operating Officer
  • , Bio & Compensation - 
  • Sharon Cohen-Vered Ph.D., Vice President - CMC & QA
  • Sheila Oren, Vice President - Clinical and Regulatory Affairs
  • Eran Shor, Vice President - Devices
  • , Bio & Compensation - 
  • Oron Yacoby-Zeevi, Vice President - Research & Development
  • Revital Mandil-Levin Ph.D., Head - Business Development
  • Shmuel Cabilly, Director

When did Neuroderm IPO?

(NDRM) raised $45 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 4,500,000 shares at a price of $10.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Roth Capital Partners were co-managers.

Has Neuroderm been receiving favorable news coverage?

Media coverage about NDRM stock has been trending somewhat positive on Sunday, Accern Sentiment reports. Accern rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neuroderm earned a news sentiment score of 0.08 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.31 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Neuroderm?

Shares of NDRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neuroderm's stock price today?

One share of NDRM stock can currently be purchased for approximately $38.85.

How big of a company is Neuroderm?

Neuroderm has a market capitalization of $1.02 billion. Neuroderm employs 55 workers across the globe.

How can I contact Neuroderm?

Neuroderm's mailing address is 3 Pekeris Street, Ruhrberg Science Bldg. Rabin Science Park Bell Entrance, REHOVOT, 7670212, Israel. The biotechnology company can be reached via phone at +972-8-9462729.


MarketBeat Community Rating for Neuroderm (NDRM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  171 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  316
MarketBeat's community ratings are surveys of what our community members think about Neuroderm and other stocks. Vote "Outperform" if you believe NDRM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NDRM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Neuroderm (NASDAQ:NDRM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Neuroderm in the last 12 months. Their average twelve-month price target is $41.8333, suggesting that the stock has a possible upside of 7.68%. The high price target for NDRM is $47.00 and the low price target for NDRM is $39.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.632.63
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $41.8333$41.8333$45.8571$45.8571
Price Target Upside: 7.68% upside8.38% upside18.80% upside18.80% upside

Neuroderm (NASDAQ:NDRM) Consensus Price Target History

Price Target History for Neuroderm (NASDAQ:NDRM)

Neuroderm (NASDAQ:NDRM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/14/2017Jefferies GroupReiterated RatingBuy$42.00LowView Rating Details
8/2/2017Roth CapitalDowngradeBuy ➝ Neutral$33.00 ➝ $39.00LowView Rating Details
7/24/2017Raymond JamesDowngradeOutperform ➝ Market Perform$39.00HighView Rating Details
7/21/2017Deutsche BankInitiated CoverageBuy ➝ Buy$47.00HighView Rating Details
6/14/2017CIBCUpgradeMarket Perform ➝ Outperform$42.00HighView Rating Details
6/14/2017OppenheimerUpgradeMarket Perform ➝ Outperform$42.00HighView Rating Details
3/7/2017CitigroupDowngradeOutperform ➝ Market PerformN/AView Rating Details
3/1/2017CowenBoost Price TargetOutperform$38.00 ➝ $70.00N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Neuroderm (NASDAQ:NDRM) Earnings History and Estimates Chart

Earnings by Quarter for Neuroderm (NASDAQ:NDRM)

Neuroderm (NASDAQ NDRM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.47)($0.57)ViewN/AView Earnings Details
5/11/20173/31/2017($0.38)($0.25)ViewN/AView Earnings Details
3/30/201712/31/2016($0.46)($0.49)ViewN/AView Earnings Details
11/10/20169/30/2016($0.42)($0.42)ViewN/AView Earnings Details
8/25/2016Q2($0.32)($0.32)ViewListenView Earnings Details
5/26/2016Q1($0.3530)($0.25)ViewListenView Earnings Details
3/31/2016Q4($0.29)($0.31)ViewListenView Earnings Details
11/11/2015Q315($0.34)($0.07)ViewListenView Earnings Details
8/6/2015Q215($0.20)($0.34)ViewListenView Earnings Details
5/27/2015Q115($0.28)($0.09)ViewListenView Earnings Details
4/2/2015Q4 2014($0.35)($2.55)ViewN/AView Earnings Details
12/18/2014Q3 2014($10.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Neuroderm (NASDAQ:NDRM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Neuroderm (NASDAQ NDRM) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 52.39%
Insider Trading History for Neuroderm (NASDAQ:NDRM)
Insider Trading History for Neuroderm (NASDAQ:NDRM)

Neuroderm (NASDAQ NDRM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Neuroderm (NASDAQ NDRM) News Headlines

Source:
DateHeadline
Acorda Therapeutics investor calls for company to explore saleAcorda Therapeutics investor calls for company to explore sale
finance.yahoo.com - May 5 at 8:58 AM
Mitsubishi Tanabe Pharma America and NeuroDerm Announce Parkinsons Disease Presentations at American Academy of Neurology Annual MeetingMitsubishi Tanabe Pharma America and NeuroDerm Announce Parkinson's Disease Presentations at American Academy of Neurology Annual Meeting
www.bizjournals.com - April 18 at 5:18 PM
Neuroderm (NDRM) Stock Rating Upgraded by BidaskClubNeuroderm (NDRM) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 16 at 9:16 AM
Zacks Investment Research Downgrades Neuroderm (NDRM) to SellZacks Investment Research Downgrades Neuroderm (NDRM) to Sell
www.americanbankingnews.com - April 11 at 5:37 PM
Neuroderm (NDRM) Upgraded to Hold by Zacks Investment ResearchNeuroderm (NDRM) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - April 6 at 6:29 PM
Head-To-Head Survey: Neuroderm (NDRM) & Tobira Therapeutics (TBRA)Head-To-Head Survey: Neuroderm (NDRM) & Tobira Therapeutics (TBRA)
www.americanbankingnews.com - March 19 at 12:26 PM
Neuroderm Ltd (NDRM) Given Consensus Rating of "Buy" by BrokeragesNeuroderm Ltd (NDRM) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 8 at 8:00 AM
Neuroderm Ltd (NDRM) Receives Average Rating of "Buy" from BrokeragesNeuroderm Ltd (NDRM) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 14 at 7:44 AM
Critical Comparison: Dynavax Technologies (DVAX) and Neuroderm (NDRM)Critical Comparison: Dynavax Technologies (DVAX) and Neuroderm (NDRM)
www.americanbankingnews.com - December 6 at 3:08 PM
Analyzing Neuroderm (NDRM) and Acorda Therapeutics (ACOR)Analyzing Neuroderm (NDRM) and Acorda Therapeutics (ACOR)
www.americanbankingnews.com - November 22 at 5:26 AM
Neuroderm Ltd (NDRM) Given Average Rating of "Buy" by AnalystsNeuroderm Ltd (NDRM) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 19 at 8:31 AM
NeuroDerm (NDRM) and The Competition Financial ContrastNeuroDerm (NDRM) and The Competition Financial Contrast
www.americanbankingnews.com - October 30 at 9:22 PM
NeuroDerm Ltd. (NDRM) Given Consensus Recommendation of "Buy" by BrokeragesNeuroDerm Ltd. (NDRM) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 25 at 11:01 AM
Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm - GlobeNewswire (press release)Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm - GlobeNewswire (press release)
globenewswire.com - October 19 at 6:40 AM
Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDermMitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm
feeds.benzinga.com - October 18 at 4:46 AM
Zacks: Analysts Expect NeuroDerm Ltd. (NDRM) Will Post Earnings of -$0.52 Per ShareZacks: Analysts Expect NeuroDerm Ltd. (NDRM) Will Post Earnings of -$0.52 Per Share
www.americanbankingnews.com - October 15 at 12:08 AM
Zacks Investment Research Downgrades Neuroderm Ltd (NDRM) to SellZacks Investment Research Downgrades Neuroderm Ltd (NDRM) to Sell
www.americanbankingnews.com - October 8 at 11:50 PM
Critical Review: NeuroDerm (NDRM) versus Its CompetitorsCritical Review: NeuroDerm (NDRM) versus Its Competitors
www.americanbankingnews.com - October 2 at 2:22 AM
NeuroDerm Ltd. (NDRM) Given Average Recommendation of "Buy" by AnalystsNeuroDerm Ltd. (NDRM) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 30 at 10:42 AM
NeuroDerm Ltd. (NDRM) Short Interest UpdateNeuroDerm Ltd. (NDRM) Short Interest Update
www.americanbankingnews.com - September 30 at 3:26 AM
NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation - GlobeNewswire (press release)NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation - GlobeNewswire (press release)
globenewswire.com - September 14 at 8:11 AM
NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma CorporationNeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation
finance.yahoo.com - September 13 at 7:01 AM
NeuroDerm Ltd. (NDRM) Given Average Rating of "Buy" by AnalystsNeuroDerm Ltd. (NDRM) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - September 5 at 10:44 AM
NeuroDerm Ltd. (NDRM) Short Interest Down 29.2% in AugustNeuroDerm Ltd. (NDRM) Short Interest Down 29.2% in August
www.americanbankingnews.com - August 29 at 1:06 AM
Stocks Under Scanner in the Biotech Space -- Merrimack Pharma, MannKind, NeuroDerm, and Celsion - PR Newswire (press release)Stocks Under Scanner in the Biotech Space -- Merrimack Pharma, MannKind, NeuroDerm, and Celsion - PR Newswire (press release)
www.prnewswire.com - August 23 at 9:05 AM
Equities Analysts Offer Predictions for NeuroDerm Ltd.s Q3 2017 Earnings (NDRM)Equities Analysts Offer Predictions for NeuroDerm Ltd.'s Q3 2017 Earnings (NDRM)
www.americanbankingnews.com - August 18 at 6:42 AM
NeuroDerm Ltd. (NASDAQ:NDRM) Rating Reiterated by Jefferies Group LLCNeuroDerm Ltd. (NASDAQ:NDRM) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - August 14 at 6:06 AM
NeuroDerm Ltd. (NASDAQ:NDRM) Receives Average Rating of "Hold" from BrokeragesNeuroDerm Ltd. (NASDAQ:NDRM) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 11 at 6:18 PM
NeuroDerm Announces Second Quarter 2017 Financial ResultsNeuroDerm Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 4 at 6:15 AM
Roth Capital Downgrades NeuroDerm Ltd. (NDRM) to NeutralRoth Capital Downgrades NeuroDerm Ltd. (NDRM) to Neutral
www.americanbankingnews.com - August 2 at 8:44 AM
NeuroDerm Announces Extraordinary General Meeting of Shareholders to Approve Acquisition by Mitsubishi Tanabe Pharma CorporationNeuroDerm Announces Extraordinary General Meeting of Shareholders to Approve Acquisition by Mitsubishi Tanabe Pharma Corporation
finance.yahoo.com - August 2 at 6:14 AM
NeuroDerm (NDRM) Catches Eye: Stock Gains 15.5% in Session - NasdaqNeuroDerm (NDRM) Catches Eye: Stock Gains 15.5% in Session - Nasdaq
www.nasdaq.com - July 27 at 4:43 AM
Featured Company News - NeuroDerm to be acquired by Mitsubishi Tanabe Pharma Corp.Featured Company News - NeuroDerm to be acquired by Mitsubishi Tanabe Pharma Corp.
finance.yahoo.com - July 27 at 4:43 AM
NeuroDerm (NDRM) Agrees to be Acquired by Japans Mitsubishi Tanabe Pharma for $1.1BNeuroDerm (NDRM) Agrees to be Acquired by Japan's Mitsubishi Tanabe Pharma for $1.1B
www.streetinsider.com - July 26 at 4:02 AM
NeuroDerm Ltd. (NDRM) Set A New High After Bought By Mitsubishi Tanabe PharmaNeuroDerm Ltd. (NDRM) Set A New High After Bought By Mitsubishi Tanabe Pharma
www.rttnews.com - July 26 at 4:02 AM
NeuroDerm (NDRM) Catches Eye: Stock Gains 15.5% in SessionNeuroDerm (NDRM) Catches Eye: Stock Gains 15.5% in Session
finance.yahoo.com - July 26 at 4:01 AM
Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm - TheStreet.comBiotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm - TheStreet.com
www.thestreet.com - July 25 at 6:04 AM
NeuroDerm Ltd. (NDRM) Has Leaped To A New High After Merger - NasdaqNeuroDerm Ltd. (NDRM) Has Leaped To A New High After Merger - Nasdaq
www.nasdaq.com - July 25 at 6:04 AM
Japans Nikkei inches up, caught in tight range before Fed meetingJapan's Nikkei inches up, caught in tight range before Fed meeting
finance.yahoo.com - July 25 at 6:04 AM
Aussie stocks lead a rebound for Asian markets as dollar steadiesAussie stocks lead a rebound for Asian markets as dollar steadies
finance.yahoo.com - July 25 at 6:04 AM
Nikkei edges down before Fed; Topix ends below key technical levelNikkei edges down before Fed; Topix ends below key technical level
finance.yahoo.com - July 25 at 6:04 AM
Neuroderm Ltd (NDRM) Downgraded by Raymond James Financial, Inc. to "Market Perform"Neuroderm Ltd (NDRM) Downgraded by Raymond James Financial, Inc. to "Market Perform"
www.americanbankingnews.com - July 24 at 2:52 PM
NeuroDerm To Be Bought By Japans Mitsubishi Tanabe Pharma For $1.1 Blm In CashNeuroDerm To Be Bought By Japan's Mitsubishi Tanabe Pharma For $1.1 Blm In Cash
www.rttnews.com - July 24 at 7:10 AM
NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in CashNeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash
finance.yahoo.com - July 24 at 7:10 AM
Mitsubishi Tanabe Pharma to buy Israels Neuroderm for $1.1 blnMitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 bln
finance.yahoo.com - July 24 at 7:10 AM
NeuroDerm Ltd. (NASDAQ:NDRM) Coverage Initiated at Deutsche Bank AGNeuroDerm Ltd. (NASDAQ:NDRM) Coverage Initiated at Deutsche Bank AG
www.americanbankingnews.com - July 22 at 8:14 PM
Deutsche Bank Starts Neuroderm Ltd (NDRM) at Buy - StreetInsider.comDeutsche Bank Starts Neuroderm Ltd (NDRM) at Buy - StreetInsider.com
www.streetinsider.com - July 22 at 6:50 AM
Market Limps Into WeekendMarket Limps Into Weekend
finance.yahoo.com - July 22 at 6:50 AM
NeuroDerm Ltd. (NASDAQ:NDRM) Receives Average Recommendation of "Buy" from AnalystsNeuroDerm Ltd. (NASDAQ:NDRM) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 17 at 11:59 AM
NeuroDerm Ltd. (NASDAQ:NDRM) Expected to Announce Earnings of -$0.48 Per ShareNeuroDerm Ltd. (NASDAQ:NDRM) Expected to Announce Earnings of -$0.48 Per Share
www.americanbankingnews.com - July 10 at 2:15 PM

SEC Filings

Neuroderm (NASDAQ:NDRM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Neuroderm (NASDAQ:NDRM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Neuroderm (NASDAQ NDRM) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.